Market Place
Sourcing Support
Xeltis Secures €50M from EIB, Shareholders for Axess Launch
02 Dec 2025 //
PR NEWSWIRE
Xeltis Eyes Commercialization After Positive aXess Trial Results
24 Sep 2025 //
PR NEWSWIRE
Xeltis Reports Positive Data for Xabg in EU Clinical Trial
17 Jul 2025 //
PR NEWSWIRE
Xeltis passes evaluation for €10M investment from European Council
08 Apr 2025 //
PR NEWSWIRE
Xeltis adds experts in Clinical Nephrology to Medical Board
11 Mar 2025 //
PR NEWSWIRE
Xeltis Completes Enrollment In EU Trial For aXess Market Approval
07 Jan 2025 //
PR NEWSWIRE
Xeltis Gets FDA Breakthrough Device Designation for aXess
14 Nov 2024 //
PR NEWSWIRE
Xeltis Receives FDA IDE Approval For AXess Pivotal Trial
13 Jun 2024 //
PR NEWSWIRE
Xeltis Announces Latest aXess Trials Results at Charing Cross
17 Apr 2024 //
PR NEWSWIRE
Outstanding data from Xeltis aXess hemodialysis vascular conduit trial presented
17 Nov 2023 //
GLOBENEWSWIRE
Xeltis secures additional ‚¬12.5 million from European Innovation Council Fund
14 Aug 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.